Obstetrics & Gynecology Doctors in Gainesville, VA Accepting Medicare

4 Obstetrics & Gynecology doctors found. Showing 1 - 4

Dr. Eugene J Louie-ng, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 7915 Lake Manassas Drive, Suite 205, Gainesville, VA 20155 Phone: 866-775-3551    Fax: 703-365-7702

Stephanie H Spytek, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 7915 Lake Manassas Dr Ste 205, Gainesville, VA 20155 Phone: 571-261-3529    Fax: 703-753-5613

Dr. Stacy Ann-marie Dehal, M. D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 7915 Lake Manassas Dr, Suite 205, Gainesville, VA 20155 Phone: 571-261-3529    Fax: 703-753-5613

Dr. Michael S Liao, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 7915 Lake Manassas Drive, Suite 205, Gainesville, VA 20155 Phone: 866-775-3551    Fax: 703-365-7702

News Archive

CURE Foundation orders for five Varian TrueBeam stereotactic radiosurgery and radiation therapy systems

Varian Medical Systems, Inc. today announced that CURE Foundation has placed an order for five Varian TrueBeam™ systems for stereotactic radiosurgery and radiation therapy.

Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Mylan N.V. today announced the U.S. launch of Amlodipine and Valsartan Tablets, 5 mg/160 mg, 5 mg/320 mg, 10 mg/160 mg, 10 mg/320 mg, which is the generic version of Novartis' Exforge Tablets.

STAAR Surgical completes first procedures to implant Visian ICL V4c design

STAAR Surgical Company, the leading developer, manufacturer and marketer of minimally invasive refractive lenses that go inside the eye, today announced the completion of the first procedures to implant its recently CE Mark-approved Visian Implantable Collamer Lens V4c design.

Debiopharm receives AFSSAPS approval of CTA for Debio 0932 inhibitor, triggers milestone payment to Curis

Curis, Inc., announced today that its licensee Debiopharm S.A. has received approval from France's regulatory authority Agence Française de Securité Sanitaire des Produits de Santé (AFSSAPS) of a Clinical Trial Application (CTA) for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of Curis' and Debiopharm's August 2009 license agreement, Curis will receive an $8 million milestone payment from Debiopharm for the achievement of this development objective.

Read more Medical News

› Verified 9 days ago